Published in J Virol on September 09, 2009
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med (2011) 2.98
HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med (2012) 2.72
Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev (2010) 2.55
The restriction factors of human immunodeficiency virus. J Biol Chem (2012) 2.36
Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses. J Virol (2013) 2.28
Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A (2009) 2.21
Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog (2010) 2.12
Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe (2011) 2.11
Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe (2012) 2.03
The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog (2010) 1.94
Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog (2010) 1.89
HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology (2010) 1.87
Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol (2010) 1.83
BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol (2010) 1.82
Animal models for HIV/AIDS research. Nat Rev Microbiol (2012) 1.71
Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci U S A (2010) 1.71
Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol (2010) 1.69
Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol (2010) 1.67
Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol (2010) 1.61
Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol (2010) 1.60
Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog (2012) 1.60
Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A (2011) 1.56
The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog (2010) 1.52
Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol (2010) 1.47
Intrinsic cellular defenses against human immunodeficiency viruses. Immunity (2012) 1.45
Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology (2010) 1.40
Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses. J Virol (2010) 1.39
Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc Natl Acad Sci U S A (2010) 1.39
Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res Hum Retroviruses (2009) 1.35
The mouse "xenotropic" gammaretroviruses and their XPR1 receptor. Retrovirology (2010) 1.35
Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology (2010) 1.34
Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc Natl Acad Sci U S A (2010) 1.29
Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction. PLoS Pathog (2011) 1.29
Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology (2010) 1.26
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014) 1.26
Mechanism of HIV-1 virion entrapment by tetherin. PLoS Pathog (2013) 1.24
A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog (2012) 1.21
SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. PLoS Pathog (2011) 1.20
BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology (2011) 1.20
HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology (2011) 1.18
The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog (2011) 1.18
Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. J Virol (2010) 1.17
Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J Virol (2011) 1.14
Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog (2014) 1.14
Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology (2011) 1.14
Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol (2012) 1.14
Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses (2011) 1.13
Influenza virus partially counteracts restriction imposed by tetherin/BST-2. J Biol Chem (2012) 1.13
Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J Biol Chem (2010) 1.13
The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis (2011) 1.10
HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med (2010) 1.09
Counteraction of the multifunctional restriction factor tetherin. Front Microbiol (2014) 1.09
Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology (2011) 1.08
β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology (2011) 1.07
Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J Virol (2010) 1.06
Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence. Cell Logist (2011) 1.06
Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol (2011) 1.05
Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis. PLoS Pathog (2013) 1.05
Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J Virol (2011) 1.04
Tetherin inhibits prototypic foamy virus release. Virol J (2011) 1.02
Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol (2012) 1.02
Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology (2011) 1.01
BST-2 diminishes HIV-1 infectivity. J Virol (2010) 1.00
Tetherin/BST-2 is essential for the formation of the intracellular virus-containing compartment in HIV-infected macrophages. Cell Host Microbe (2012) 1.00
Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology (2012) 0.99
The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? J Interferon Cytokine Res (2010) 0.98
Regulation of porcine endogenous retrovirus release by porcine and human tetherins. J Virol (2009) 0.98
Modulation of Immune System by Kaposi's Sarcoma-Associated Herpesvirus: Lessons from Viral Evasion Strategies. Front Microbiol (2012) 0.97
Immune evasion by Kaposi's sarcoma-associated herpesvirus. Future Microbiol (2010) 0.96
Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M. J Virol (2013) 0.95
Antiretroviral restriction factors. Curr Opin Virol (2011) 0.93
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol (2011) 0.93
HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. J Virol (2010) 0.93
HIV-1 Vpu Mediates HLA-C Downregulation. Cell Host Microbe (2016) 0.93
Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin. J Gen Virol (2011) 0.92
Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein. J Virol (2012) 0.92
Cloning and characterization of the antiviral activity of feline Tetherin/BST-2. PLoS One (2011) 0.92
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
HIV-1 Vpu - an ion channel in search of a job. Biochim Biophys Acta (2013) 0.91
A tail of Tetherin: how pandemic HIV-1 conquered the world. Cell Host Microbe (2009) 0.91
The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release. J Virol (2011) 0.90
Viral takeover of the host ubiquitin system. Front Microbiol (2011) 0.90
Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation. J Virol (2014) 0.90
Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein. J Virol (2013) 0.90
The frantic play of the concealed HIV envelope cytoplasmic tail. Retrovirology (2013) 0.90
Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses. J Virol (2014) 0.89
Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons. DNA Cell Biol (2011) 0.89
Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism. Front Microbiol (2011) 0.89
Ebolavirus Replication and Tetherin/BST-2. Front Microbiol (2012) 0.88
Tetherin and its viral antagonists. J Neuroimmune Pharmacol (2011) 0.87
Vpu and BST2: Still Not There Yet? Front Microbiol (2012) 0.87
Mechanisms underlying HIV-1 Vpu-mediated viral egress. Front Microbiol (2014) 0.86
Interactions between HIV-1 and the cell-autonomous innate immune system. Cell Host Microbe (2014) 0.86
Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors. PLoS Pathog (2015) 0.85
A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress. Virology (2013) 0.84
SIV replication in human cells. Front Microbiol (2012) 0.84
A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release. Retrovirology (2013) 0.84
Antagonism to human BST-2/tetherin by Sendai virus glycoproteins. J Gen Virol (2013) 0.84
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe (2008) 9.27
Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic (2003) 5.32
HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med (2004) 5.08
Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol (2008) 4.72
Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO J (1994) 4.46
Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A (2009) 4.38
HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe (2009) 4.36
Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog (2009) 4.24
Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog (2009) 4.18
Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature (1992) 4.16
Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe (2009) 4.11
Inhibition of Lassa and Marburg virus production by tetherin. J Virol (2008) 3.98
HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog (2006) 3.97
Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol (2009) 3.67
Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog (2009) 3.66
Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog (2006) 3.57
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A (2009) 3.47
APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol (2004) 3.17
Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol (2002) 3.06
Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun (1999) 3.03
Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog (2009) 2.92
Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci (2007) 2.90
Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J Immunol (1995) 2.62
Host restriction factors blocking retroviral replication. Annu Rev Genet (2008) 2.41
A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J Biol Chem (1998) 2.40
A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J Virol (1995) 2.35
Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol (2009) 2.35
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol (2007) 2.16
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J Cell Biol (1996) 2.06
Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology (1997) 2.02
The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic (2006) 1.97
Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol (2005) 1.97
Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS Res Hum Retroviruses (1992) 1.92
A CD317/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. J Cell Biol (2009) 1.90
HIV-2: the forgotten AIDS virus. Trends Microbiol (2008) 1.66
AIDS virus envelope spike structure. Curr Opin Struct Biol (2007) 1.54
Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution? Nat Rev Microbiol (2009) 1.50
In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45
Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation. J Virol (2002) 1.37
Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology (2003) 1.32
Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J Virol (1999) 1.31
The simian immunodeficiency virus envelope glycoprotein contains multiple signals that regulate its cell surface expression and endocytosis. Traffic (2000) 1.28
Folding of viral envelope glycoproteins in the endoplasmic reticulum. Traffic (2000) 1.15
Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol (2006) 1.12
CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS (2003) 1.01
Processing and routage of HIV glycoproteins by furin to the cell surface. Virus Res (1999) 0.96
Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol (2008) 4.72
Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol (2006) 4.43
Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog (2009) 4.18
Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe (2012) 2.03
Host factors involved in retroviral budding and release. Nat Rev Microbiol (2011) 1.94
The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog (2010) 1.94
Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol (2010) 1.83
Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci U S A (2010) 1.71
Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol (2010) 1.60
A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog (2012) 1.21
Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection. Retrovirology (2013) 1.16
Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J Virol (2004) 1.16
Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses (2011) 1.13
The UBAP1 subunit of ESCRT-I interacts with ubiquitin via a SOUBA domain. Structure (2012) 1.09
Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol (2011) 1.05
Ig-like transcript 7, but not bone marrow stromal cell antigen 2 (also known as HM1.24, tetherin, or CD317), modulates plasmacytoid dendritic cell function in primary human blood leukocytes. J Immunol (2013) 1.02
An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. J Virol (2005) 1.01
Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J Gen Virol (2006) 0.89
Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses. J Virol (2014) 0.89
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology (2011) 0.85
Identification of a receptor for an extinct virus. Proc Natl Acad Sci U S A (2010) 0.84